Literature DB >> 11207054

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

C Fujiyama1, A Jones, S Fuggle, R Bicknell, D Cranston, A L Harris.   

Abstract

As well as being a passive support, the extracellular matrix also regulates key biological processes such as invasion, differentiation and angiogenesis. We have therefore developed an in vitro model of bladder cancer invasion using de-epithelialized rat bladder to allow for tumour cell-extracellular matrix interactions. Onto this we have seeded a panel of human bladder cancer cell lines (RT4, RT112, 253J and EJ28 (T24)) representing progression from well to poorly differentiated phenotypes and used as models of superficial to invasive bladder cancer. The better differentiated cell lines RT4 and RT112 reproducibly grew as stratified epithelium, whereas poorly differentiated EJ28 cells invaded across a broad front. Invasion was not simply related to proliferation rate, measured either as doubling time on plastic (non-invasive 253J and invasive EJ28 having the same doubling time) or by Ki-67 proliferation index within the model. We used the model to test the ability of 4 compounds that interfere with tumour cell-extracellular matrix interactions (suramin, N-acetylcysteine and the urokinase plasminogen activator pathway antagonists A5 compound and monoclonal antibody Mab 3936) to inhibit invasion. At non-toxic concentrations, all significantly inhibited invasion (P< 0.05), although to varying degrees, suramin and A5 almost completely and N-acetylcysteine the least. In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207054      PMCID: PMC2363759          DOI: 10.1054/bjoc.2000.1641

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  51 in total

1.  Reconstitution of human urothelium from monolayer cultures.

Authors:  S D Scriven; C Booth; D F Thomas; L K Trejdosiewicz; J Southgate
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

2.  Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.

Authors:  D Ma; R D Gerard; X Y Li; H Alizadeh; J Y Niederkorn
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

3.  Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines.

Authors:  H Miyake; K Yoshimura; I Hara; H Eto; S Arakawa; S Kamidono
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

4.  Stromal and vascular invasion in an human in vitro bladder cancer model.

Authors:  C Booth; P Harnden; L K Trejdosiewicz; S Scriven; P J Selby; J Southgate
Journal:  Lab Invest       Date:  1997-06       Impact factor: 5.662

5.  Halting angiogenesis suppresses carcinoma cell invasion.

Authors:  M Skobe; P Rockwell; N Goldstein; S Vosseler; N E Fusenig
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

7.  Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.

Authors:  P Borgström; M A Bourdon; K J Hillan; P Sriramarao; N Ferrara
Journal:  Prostate       Date:  1998-04-01       Impact factor: 4.104

8.  Intravenous administration of oral N-acetylcysteine.

Authors:  L Yip; R C Dart; K M Hurlbut
Journal:  Crit Care Med       Date:  1998-01       Impact factor: 7.598

9.  Metachronous multifocal development of urothelial cancers by intraluminal seeding.

Authors:  T Habuchi; R Takahashi; H Yamada; Y Kakehi; T Sugiyama; O Yoshida
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

10.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

Authors:  K Bajou; A Noël; R D Gerard; V Masson; N Brunner; C Holst-Hansen; M Skobe; N E Fusenig; P Carmeliet; D Collen; J M Foidart
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

View more
  9 in total

1.  Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells.

Authors:  Julia Schulte; Michaela Weidig; Philipp Balzer; Petra Richter; Marcus Franz; Kerstin Junker; Mieczyslaw Gajda; Karlheinz Friedrich; Heiko Wunderlich; Arne Östman; Iver Petersen; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2012-07-22       Impact factor: 4.304

2.  Expression of Robo protein in bladder cancer tissues and its effect on the growth of cancer cells by blocking Robo protein.

Authors:  Yang Li; Hepeng Cheng; Weibo Xu; Xin Tian; Xiaodong Li; Chaoyang Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.

Authors:  N S Brown; E H Streeter; A Jones; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

4.  Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Authors:  J J Ord; E Streeter; A Jones; K Le Monnier; D Cranston; J Crew; S P Joel; M A Rogers; R E Banks; I S D Roberts; A L Harris
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

5.  RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.

Authors:  Y Yang; H Xu; J Shen; Y Yang; S Wu; J Xiao; Y Xu; X-Y Liu; L Chu
Journal:  Cell Death Dis       Date:  2015-05-14       Impact factor: 8.469

6.  Current animal models of bladder cancer: Awareness of translatability (Review).

Authors:  Jie Ding; Ding Xu; Chunwu Pan; Min Ye; Jian Kang; Qiang Bai; Jun Qi
Journal:  Exp Ther Med       Date:  2014-07-11       Impact factor: 2.447

7.  Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation.

Authors:  Peter Torab; Yue Yan; Mona Ahmed; Hironobu Yamashita; Joshua I Warrick; Jay D Raman; David J DeGraff; Pak Kin Wong
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

Review 8.  Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Authors:  Jeffrey J Tomaszewski; Marc C Smaldone
Journal:  Open Access J Urol       Date:  2010-05-19

9.  Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer.

Authors:  Scott Palmer; Karina Litvinova; Andrey Dunaev; Stewart Fleming; David McGloin; Ghulam Nabi
Journal:  Biomed Opt Express       Date:  2016-03-07       Impact factor: 3.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.